Tango Therapeutics Rises on Early-Stage Data for Vopimetostat in Pancreatic Cancer
Tango Therapeutics (NASDAQ: TNGX) is up approximately 32% following the release of early data from a phase 1/2 trial combining vopimetostat with Revolution Medicines' drugs. The treatment showed promise for second or third-line patients with MTAP-deleted pancreatic cancer.
Topics: biotech cancer research drug development